Lionco Pharmaceutical Group Co.,Ltd.

603669

CNE1000022R8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
4.99 ^CNY	-1.58%		+1.63%	-9.76%

19/04	Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
31/01	Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	CI

Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.

January 11, 2023

From January 1, 2023 to January 9, 2023, the company has repurchased 614,400 shares, for CNY 3.75 million. With this, the company has completed the repurchase of 8,915,893 shares, for CNY 60 million under the buyback announced on March 10, 2022.

Latest news about Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	31/01	CI
Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback announced on January 31, 2023, has closed with 8,785,900 shares, representing 1.22% for CNY 50 million.	28/01	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	03/01	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	14/11	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	14/11	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	14/11	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	20/23/20	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Lionco Pharma Registers Latamoxef Sodium for Injection in China	04/23/04	MT
Lionco Pharma's Bacterial Drug Passes Regulator's Evaluation	21/23/21	MT
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
Lionco Pharma Unit's Aztreonam for Injection Passes Drug Regulator's Evaluation	18/23/18	MT
Lionco Pharma to Raise Up to 100 Million Yuan Through Share Buyback	31/23/31	MT
Lionco Pharmaceutical Group Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	31/23/31	CI
Lionco Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.	29/23/29	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	11/23/11	CI
Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback announced on March 10, 2022 has closed with 8,915,893 shares, for CNY 60 million.	09/23/09	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	06/23/06	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	11/22/11	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	05/22/05	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	30/22/30	CI

Chart Lionco Pharmaceutical Group Co.,Ltd.

Duration

Period

Chart Lionco Pharmaceutical Group Co.,Ltd.

More charts

Company Profile

Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.

Sector

Pharmaceuticals

Calendar

14/06/2024 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
LIONCO PHARMACEUTICAL GROUP CO.,LTD.	-9.76%	485M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B